Cerebellum’s ResMed RMD Stock Holding History

Cerebellum’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-150	Closed	-$17K	–	528
2018 Q4	$17K	Sell	150 -1,463	-91%	-$157K	0.01%	404
2018 Q3	$186K	Buy	+1,613	New	+$177K	0.3%	123

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cerebellum's RMD Position: Q1 2019 in Review

Cerebellum sold out of ResMed (RMD) in Q1 2019, closing a stake of 150 shares — an estimated $17K sold.

Cerebellum first reported a position in RMD in Q3 2018 and held it in 2 quarters. The position peaked at $186K in Q3 2018. 477 funds tracked by Wall St. Rank hold RMD as of Q1 2019.

Cerebellum reported no remaining ResMed position as of Q1 2019 after selling out during the quarter.
Cerebellum sold 150 ResMed shares in Q1 2019, an estimated $17K.
Cerebellum first reported a position in ResMed in Q3 2018 and held it in 2 quarters.
Cerebellum's ResMed position peaked at $186K in Q3 2018.
477 funds tracked by Wall St. Rank held ResMed as of Q1 2019.

Based on Cerebellum's 13F filing for Q1 2019, filed 21 May 2019.